Literature DB >> 11348723

Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.

J W Hodge1, D W Grosenbach, A N Rad, M Giuliano, H Sabzevari, J Schlom.   

Abstract

Recombinant orthopox vectors (both replication-defective fowlpox [rF], and replication competent vaccinia [rV] have been developed that simultaneously express three T-cell costimulatory molecule transgenes. The constituents of this triad of costimulatory molecules (designated TRICOM) are B7-1, ICAM-1, and LFA-3. We have previously shown that infection of murine dendritic cells (DCs) with TRICOM vectors increases their level of expression of the triad of costimulatory molecules and enhances the efficacy of DCs to activate T cells. While DCs are arguably the most potent antigen presenting cell (APC), limitations clearly exist in their use due to the level of effort and cost for their generation. The studies reported here demonstrate that a generic APC population, murine splenocytes, can be made markedly more efficient as APCs by infection with either rF-TRICOM or rV-TRICOM vectors. Infection of splenocytes with either TRICOM vector led to significant improvement of APC capabilities in terms of: (a) enhancement of mixed lymphocyte reactions; (b) a reduction in the amount of signal 1 to activate naive T cells; and (c) a reduction in the amount of APCs required to activate T cells using a constant amount of signal 1. TRICOM-enhanced T-cell activation was shown to correspond to increases in type-1 cytokines and a reduced level of apoptosis, compared with T cells activated with uninfected or control vector-infected splenocytes. In vitro and in vivo experiments compared DCs with TRICOM-infected splenocytes. Infection of splenocytes with TRICOM vectors markedly enhanced their ability to activate T cells to levels approaching that of DCs. These studies thus demonstrate for the first time that an abundant and accessible population of APCs obtainable without lengthy culture or the use of costly exogenous cytokines (in contrast to that of DCs) can be made more potent as APCs with the use of vectors that express a triad of costimulatory molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11348723     DOI: 10.1016/s0264-410x(01)00062-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Authors:  Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong Y Tsang
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

3.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

4.  Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.

Authors:  Dmitry Isakov; Amiran Dzutsev; Jay A Berzofsky; Igor M Belyakov
Journal:  Eur J Immunol       Date:  2011-12       Impact factor: 5.532

5.  Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.

Authors:  Mary T Litzinger; Kenneth A Foon; Kwong-Yok Tsang; Jeffrey Schlom; Claudia Palena
Journal:  Leuk Res       Date:  2010-01-31       Impact factor: 3.156

6.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

Review 7.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.